PT  - JOURNAL ARTICLE
AU  - Carbonati, Tanner
AU  - Eslami, Parastou
AU  - Waks, Jonathan W.
AU  - Fiorina, Laurent
AU  - Chaudhari, Ashish
AU  - Henry, Christine
AU  - Johnson, Alistair E.W.
AU  - Pollard, Tom
AU  - Gow, Brian
AU  - Mark, Roger G.
AU  - Horng, Steven
AU  - Greenbaum, Nathaniel R.
TI  - Deep neural networks detect regional wall motion abnormalities and preclinical cardiovascular disease from 12-lead ECGs
AID  - 10.1101/2024.05.31.24308304
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.31.24308304
4099  - http://medrxiv.org/content/early/2024/06/01/2024.05.31.24308304.short
4100  - http://medrxiv.org/content/early/2024/06/01/2024.05.31.24308304.full
AB  - Background Identifying regional wall motion abnormalities (RWMAs) is critical for diagnosing and risk stratifying patients with cardiovascular disease, particularly ischemic heart disease. We hypothesized that a deep neural network could accurately identify patients with regional wall motion abnormalities from a readily available standard 12-lead electrocardiogram (ECG).Methods This observational, retrospective study included patients who were treated at Beth Israel Deaconess Medical Center and had an ECG and echocardiogram performed within 14 days of each other between 2008 and 2019. We trained a convolutional neural network to detect the presence of RWMAs, qualitative global right ventricular (RV) hypokinesis, and varying degrees of left ventricular dysfunction (left ventricular ejection fraction [LVEF] ≤50%, LVEF ≤40%, and LVEF ≤35%) identified by echocardiography, using ECG data alone. Patients were randomly split into development (80%) and test sets (20%). Model performance was assessed using area under the receiver operating characteristic curve (AUC). Cox proportional hazard models adjusted for age and sex were performed to estimate the risk of future acute coronary events.Results The development set consisted of 19,837 patients (mean age 66.7±16.4; 46.7% female) and the test set comprised of 4,953 patients (mean age 67.5±15.8 years; 46.5% female). On the test dataset, the model accurately identified the presence of RWMA, RV hypokinesis, LVEF ≤50%, LVEF ≤40%, and LVEF ≤35% with AUCs of 0.87 (95% CI 0.858-0.882), 0.888 (95% CI 0.878-0.899), 0.923 (95% CI 0.914-0.933), 0.93 (95% CI 0.921-0.939), and 0.876 (95% CI 0.858-0.896), respectively. Among patients with normal biventricular function at the time of the index ECG, those classified as having RMWA by the model were 3 times the risk (age- and sex-adjusted hazard ratio, 2.8; 95% CI 1.9-3.9) for future acute coronary events compared to those classified as negative.Conclusions We demonstrate that a deep neural network can help identify regional wall motion abnormalities and reduced LV function from a 12-lead ECG and could potentially be used as a screening tool for triaging patients who need either initial or repeat echocardiographic imaging.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCollection of the MIMIC-IV-ECG and MIMIC-IV-ECHO dataset was funded by the Massachusetts Life Sciences Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center (Boston, MA) and the Massachusetts Institute of Technology (Cambridge, MA). Requirement for individual patient consent was waived because the project did not impact clinical care and all protected health information was deidentified.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used for the study was collected from three public databases, Medical Information Mart for Intensive Care (MIMIC)-IV-ECG, MIMIC-IV-Note, and MIMIC-IV-ECHO. Clinical data linked to patients included in the study was matched using the publicly available database, MIMIC-IV https://physionet.org/content/mimic-iv-echo/0.1/ https://physionet.org/content/mimic-iv-ecg/1.0/